Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About iCeutica

iCeutica offers a nano-sizing platform that aims to provide a simple and scalable process to reformulate a range of different drugs. In April 2011, iCeutica was acquired by Iroko Pharmaceuticals. The valuation of iCeutica was undisclosed. Other terms of the deal were not released.

Headquarters Location

One Crescent Drive Suite 400

Philadelphia, Pennsylvania, 19112,

United States


Missing: iCeutica's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: iCeutica's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

iCeutica Patents

iCeutica has filed 76 patents.

The 3 most popular patent topics include:

  • Pharmacokinetics
  • Analgesics
  • Barbiturates
patents chart

Application Date

Grant Date


Related Topics




Selective estrogen receptor modulators, Phenols, Hormonal antineoplastic drugs, Estranes, Synthetic estrogens


Application Date


Grant Date



Related Topics

Selective estrogen receptor modulators, Phenols, Hormonal antineoplastic drugs, Estranes, Synthetic estrogens



Latest iCeutica News

iCeutica Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

Jan 5, 2017

iCeutica Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 08:45 EST 5 Jan 2017 | BioPortfolio Reports Home » Topics » Pain » Latest News » iCeutica Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 Summary iCeutica Inc iCeutica, a subsidiary of Iroko Holdings SA is a pharmaceutical company that develops medicines for clinical diseases. The company offers products for the treatment of pain and inflammation, oncology , respiratory diseases and migraine, among others. Its SoluMatrix Fine Particle Technology is used for product development with broad therapeutic applications. The company's SoluMatrix develops submicronsized drug particles. iCeutica partners with other pharmaceuticals and biotechnology companies. The company operates through its research and development facilities in King of Prussia and Pennsylvania. iCeutica is headquartered in Philadelphia, Pennsylvania, the US. iCeutica Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

iCeutica Frequently Asked Questions (FAQ)

  • When was iCeutica founded?

    iCeutica was founded in 2003.

  • Where is iCeutica's headquarters?

    iCeutica's headquarters is located at One Crescent Drive, Philadelphia.

  • What is iCeutica's latest funding round?

    iCeutica's latest funding round is Acquired.

  • How much did iCeutica raise?

    iCeutica raised a total of $1.01M.

  • Who are the investors of iCeutica?

    Investors of iCeutica include Iroko Pharmaceuticals.

  • Who are iCeutica's competitors?

    Competitors of iCeutica include Humanetics, Embera NeuroTherapeutics, Profectus BioSciences, Vistagen, CoMentis and 13 more.

Compare iCeutica to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Adipogen Pharmaceuticals

Adipogen is developing drugs to treat obesity based on discoveries from the University of Queensland.


OyaGen is a biotechnology company discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company will pursue several assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.

Jenrin Discovery

Jenrin Discovery, Inc. is developing drugs for the treatment of diabetes and related disorders, by modifying known drugs with CNS side effects to keep them out of the brain. Jenrin has completed initial proof of concept work in animals in their CB1 antagonist program. Additionally, the company is working on peripherally restricted MAO inhibitors, and several other programs.

Ethos Pharmaceuticals

Developer of novel variants of peptide drugs.


SBIO is focused on the discovery and development of small molecule oncology drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.